Here we describe three gynecologic cancer patients with HER2 mutations: two cases with tumor HER2 expression levels of 0 by IHC, and one case with unknown HER2 expression level by IHC who clinically responded well to T-DXd therapy. The gene discussed is ERBB2; the disease is female reproductive organ cancer.